Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!
Jiang Nan, Yang Yong-Ge, Xu Xue-Ting, Zhao Gang-Tao. Determination of Atorvastatin in human plasma by LC-MS-MS[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 15-16,70.
Citation:
Jiang Nan, Yang Yong-Ge, Xu Xue-Ting, Zhao Gang-Tao. Determination of Atorvastatin in human plasma by LC-MS-MS[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 15-16,70.
Determination of Atorvastatin in human plasma by LC-MS-MS
Department of Pharmacy,General Hospital of Beijing Military Command of PLA,Beijing 100700,China
Received Date: 2010-05-18
Rev Recd Date:
2010-09-09
Abstract
Objective To establish a method for determining Atorvastatin in human plasma by LC-MS-MS. Methods Atorvastatin was extracted for determination by LC-MS-MS. Analytical column was Thermo BioBasic-C8(2.1 mm×100 mm,5 μm). The mobile phase was acetonitrile(0.1%acid):water(0.1%acid)=70:30. Mass spectrum conditions was ESI performing in the SRM mode using target ions m/z 558→278(30EV)(Atorvastatin ), m/z 269→106(22 EV)(tolbutamide), SP 3 500 KV, SGP 10 Arb, AGP 15 Arb, TEM 314 ℃. Results The calibration curve was linear over the range of 0.1~20 μg/L. The LLOQ of Atorvastatin in plasma was 0.1 μg/L. The extracted recovery was>70%. The intra-and inter-day RSD were<15%. Conclusion The method is sensitive, simple and accurate to determinate Atorvastatin plasma concentration and suitable to study phase I clinical test of Atorvastatin.
Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management og hypercholesterolaemia[J]. Drμgs, 1996, 51: 433.
[2]
Naoumova RP, Marais AD, Mountney J,et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis, 1996, 119: 203.
Abstract: Objective To establish a method for determining Atorvastatin in human plasma by LC-MS-MS. Methods Atorvastatin was extracted for determination by LC-MS-MS. Analytical column was Thermo BioBasic-C8(2.1 mm×100 mm,5 μm). The mobile phase was acetonitrile(0.1%acid):water(0.1%acid)=70:30. Mass spectrum conditions was ESI performing in the SRM mode using target ions m/z 558→278(30EV)(Atorvastatin ), m/z 269→106(22 EV)(tolbutamide), SP 3 500 KV, SGP 10 Arb, AGP 15 Arb, TEM 314 ℃. Results The calibration curve was linear over the range of 0.1~20 μg/L. The LLOQ of Atorvastatin in plasma was 0.1 μg/L. The extracted recovery was>70%. The intra-and inter-day RSD were<15%. Conclusion The method is sensitive, simple and accurate to determinate Atorvastatin plasma concentration and suitable to study phase I clinical test of Atorvastatin.
Jiang Nan, Yang Yong-Ge, Xu Xue-Ting, Zhao Gang-Tao. Determination of Atorvastatin in human plasma by LC-MS-MS[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 15-16,70.
Citation:
Jiang Nan, Yang Yong-Ge, Xu Xue-Ting, Zhao Gang-Tao. Determination of Atorvastatin in human plasma by LC-MS-MS[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 15-16,70.
Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management og hypercholesterolaemia[J]. Drμgs, 1996, 51: 433.
[2]
Naoumova RP, Marais AD, Mountney J,et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis, 1996, 119: 203.